Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants

Eirwen M. Miller, Nicole E. Patterson, Jenna Marcus Zechmeister, Michal Bejerano-Sagie, Maria Delio, Kunjan Patel, Nivedita Ravi, Wilber Quispe-Tintaya, Alexander Maslov, Nichelle Simmons, Maria Castaldi, Jan Vijg, Rouzan G. Karabakhtsian, John M. Greally, Dennis Yi-Shin Kuo, Cristina Montagna

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Next generation sequencing (NGS) technologies have revolutionized our approach to genomic research. The use of whole genome sequencing (WGS), whole exome sequencing (WES), transcriptome profiling, and targeted DNA sequencing has exponentially improved our understanding of the human genome and the genetic complexities underlying malignancy. Yet, WGS and WES clinical applications remain limited due to high costs and the large volume of data generated. When utilized to address biological questions in basic science studies, targeted sequencing panels have proven extremely valuable due to reduced costs and higher sequencing depth. However, the routine application of targeted sequencing to the clinical setting is limited to a few cancer subtypes. Some highly aggressive tumor types, like type 2 endometrial cancer (EC), could greatly benefit from routine genomic analysis using targeted sequencing. To explore the potential utility of a mid size panel (~150 genes) in the clinical setting, we developed and validated a custom panel against WGS, WES, and another commercially available targeted panel. Our results indicate that a mid size custom designed panel is as efficient as WGS and WES in mapping variants of biological and clinical relevance, rendering higher coverage, at a lower cost, with fewer variants of uncertain significance. Because of the much higher sequencing depth that could be achieved, our results demonstrate that targeted sequencing outperformed WGS and WES in the mapping of pathogenic variants in a breast cancer case, as well as a case of mixed serous and high-grade endometrioid EC, the most aggressive EC subtype.

Original languageEnglish (US)
Pages (from-to)102033-102045
Number of pages13
JournalOncotarget
Volume8
Issue number60
DOIs
StatePublished - Jan 1 2017

Fingerprint

Exome
DNA Sequence Analysis
Genome
Endometrial Neoplasms
Costs and Cost Analysis
Neoplasms
Medical Genetics
Gene Expression Profiling
Human Genome
Breast Neoplasms
Technology
Research
Genes

Keywords

  • Endometrial carcinoma
  • Next generation sequencing
  • Target sequencing
  • Tumor recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. / Miller, Eirwen M.; Patterson, Nicole E.; Zechmeister, Jenna Marcus; Bejerano-Sagie, Michal; Delio, Maria; Patel, Kunjan; Ravi, Nivedita; Quispe-Tintaya, Wilber; Maslov, Alexander; Simmons, Nichelle; Castaldi, Maria; Vijg, Jan; Karabakhtsian, Rouzan G.; Greally, John M.; Kuo, Dennis Yi-Shin; Montagna, Cristina.

In: Oncotarget, Vol. 8, No. 60, 01.01.2017, p. 102033-102045.

Research output: Contribution to journalArticle

Miller, Eirwen M. ; Patterson, Nicole E. ; Zechmeister, Jenna Marcus ; Bejerano-Sagie, Michal ; Delio, Maria ; Patel, Kunjan ; Ravi, Nivedita ; Quispe-Tintaya, Wilber ; Maslov, Alexander ; Simmons, Nichelle ; Castaldi, Maria ; Vijg, Jan ; Karabakhtsian, Rouzan G. ; Greally, John M. ; Kuo, Dennis Yi-Shin ; Montagna, Cristina. / Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. In: Oncotarget. 2017 ; Vol. 8, No. 60. pp. 102033-102045.
@article{0a7f0abed4bd4ef9a4f6e6be709990ed,
title = "Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants",
abstract = "Next generation sequencing (NGS) technologies have revolutionized our approach to genomic research. The use of whole genome sequencing (WGS), whole exome sequencing (WES), transcriptome profiling, and targeted DNA sequencing has exponentially improved our understanding of the human genome and the genetic complexities underlying malignancy. Yet, WGS and WES clinical applications remain limited due to high costs and the large volume of data generated. When utilized to address biological questions in basic science studies, targeted sequencing panels have proven extremely valuable due to reduced costs and higher sequencing depth. However, the routine application of targeted sequencing to the clinical setting is limited to a few cancer subtypes. Some highly aggressive tumor types, like type 2 endometrial cancer (EC), could greatly benefit from routine genomic analysis using targeted sequencing. To explore the potential utility of a mid size panel (~150 genes) in the clinical setting, we developed and validated a custom panel against WGS, WES, and another commercially available targeted panel. Our results indicate that a mid size custom designed panel is as efficient as WGS and WES in mapping variants of biological and clinical relevance, rendering higher coverage, at a lower cost, with fewer variants of uncertain significance. Because of the much higher sequencing depth that could be achieved, our results demonstrate that targeted sequencing outperformed WGS and WES in the mapping of pathogenic variants in a breast cancer case, as well as a case of mixed serous and high-grade endometrioid EC, the most aggressive EC subtype.",
keywords = "Endometrial carcinoma, Next generation sequencing, Target sequencing, Tumor recurrence",
author = "Miller, {Eirwen M.} and Patterson, {Nicole E.} and Zechmeister, {Jenna Marcus} and Michal Bejerano-Sagie and Maria Delio and Kunjan Patel and Nivedita Ravi and Wilber Quispe-Tintaya and Alexander Maslov and Nichelle Simmons and Maria Castaldi and Jan Vijg and Karabakhtsian, {Rouzan G.} and Greally, {John M.} and Kuo, {Dennis Yi-Shin} and Cristina Montagna",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.22116",
language = "English (US)",
volume = "8",
pages = "102033--102045",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "60",

}

TY - JOUR

T1 - Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants

AU - Miller, Eirwen M.

AU - Patterson, Nicole E.

AU - Zechmeister, Jenna Marcus

AU - Bejerano-Sagie, Michal

AU - Delio, Maria

AU - Patel, Kunjan

AU - Ravi, Nivedita

AU - Quispe-Tintaya, Wilber

AU - Maslov, Alexander

AU - Simmons, Nichelle

AU - Castaldi, Maria

AU - Vijg, Jan

AU - Karabakhtsian, Rouzan G.

AU - Greally, John M.

AU - Kuo, Dennis Yi-Shin

AU - Montagna, Cristina

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Next generation sequencing (NGS) technologies have revolutionized our approach to genomic research. The use of whole genome sequencing (WGS), whole exome sequencing (WES), transcriptome profiling, and targeted DNA sequencing has exponentially improved our understanding of the human genome and the genetic complexities underlying malignancy. Yet, WGS and WES clinical applications remain limited due to high costs and the large volume of data generated. When utilized to address biological questions in basic science studies, targeted sequencing panels have proven extremely valuable due to reduced costs and higher sequencing depth. However, the routine application of targeted sequencing to the clinical setting is limited to a few cancer subtypes. Some highly aggressive tumor types, like type 2 endometrial cancer (EC), could greatly benefit from routine genomic analysis using targeted sequencing. To explore the potential utility of a mid size panel (~150 genes) in the clinical setting, we developed and validated a custom panel against WGS, WES, and another commercially available targeted panel. Our results indicate that a mid size custom designed panel is as efficient as WGS and WES in mapping variants of biological and clinical relevance, rendering higher coverage, at a lower cost, with fewer variants of uncertain significance. Because of the much higher sequencing depth that could be achieved, our results demonstrate that targeted sequencing outperformed WGS and WES in the mapping of pathogenic variants in a breast cancer case, as well as a case of mixed serous and high-grade endometrioid EC, the most aggressive EC subtype.

AB - Next generation sequencing (NGS) technologies have revolutionized our approach to genomic research. The use of whole genome sequencing (WGS), whole exome sequencing (WES), transcriptome profiling, and targeted DNA sequencing has exponentially improved our understanding of the human genome and the genetic complexities underlying malignancy. Yet, WGS and WES clinical applications remain limited due to high costs and the large volume of data generated. When utilized to address biological questions in basic science studies, targeted sequencing panels have proven extremely valuable due to reduced costs and higher sequencing depth. However, the routine application of targeted sequencing to the clinical setting is limited to a few cancer subtypes. Some highly aggressive tumor types, like type 2 endometrial cancer (EC), could greatly benefit from routine genomic analysis using targeted sequencing. To explore the potential utility of a mid size panel (~150 genes) in the clinical setting, we developed and validated a custom panel against WGS, WES, and another commercially available targeted panel. Our results indicate that a mid size custom designed panel is as efficient as WGS and WES in mapping variants of biological and clinical relevance, rendering higher coverage, at a lower cost, with fewer variants of uncertain significance. Because of the much higher sequencing depth that could be achieved, our results demonstrate that targeted sequencing outperformed WGS and WES in the mapping of pathogenic variants in a breast cancer case, as well as a case of mixed serous and high-grade endometrioid EC, the most aggressive EC subtype.

KW - Endometrial carcinoma

KW - Next generation sequencing

KW - Target sequencing

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=85034857870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034857870&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.22116

DO - 10.18632/oncotarget.22116

M3 - Article

VL - 8

SP - 102033

EP - 102045

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 60

ER -